Moderna Shares Triple on Melanoma Vaccine Data
Moderna shares nearly tripled on Wednesday after a late-stage melanoma vaccine trial validated the company's mRNA platform beyond Covid, triggering a
Keytruda
Every Fin-node story mentioning Keytruda — 1 story, newest first.
Keytruda · 1 story